Genetic Evolution in BRCA1 ‐Associated Breast Cancer Reveals Early Driver Mutations Shaping Tumor Features and Prognosis
Authors:
Open Access
- 3 July 2026
- journal article
- Published by Wiley in Cancer Science
- Vol. 117 (10) , 2863-2876
Abstract
Pathogenic germline variants in the BRCA1 gene significantly increase the lifetime risk of breast cancer and are frequently associated with early‐onset and triple‐negative disease. However, the chronology of genetic events during breast tumor evolution in BRCA1 carriers remains unclear. In this study, 57 primary breast tumors from 57 BRCA1 carriers were analyzed, including formalin‐fixed paraffin‐embedded specimens and fresh‐frozen specimens. Formalin‐fixed paraffin‐embedded tumors were microdissected into normal mammary tissue, carcinoma in situ, and invasive carcinoma components for deep target‐region sequencing, whereas fresh‐frozen tumors underwent whole‐exome sequencing and bulk transcriptome sequencing. Compared with non‐carriers from The Cancer Genome Atlas, breast cancers from BRCA1 carriers showed a distinct mutational landscape characterized by a high prevalence of TP53 mutations and a reduced frequency of PIK3CA and GATA3 alterations. Based on the initiating driver event, BRCA1 ‐associated tumors were classified into three subgroups: TP53 , PI(3)K‐AKT pathway, and unclassified. The TP53 ‐driven subgroup was strongly associated with the triple‐negative phenotype, loss of heterozygosity at the BRCA1 locus, and elevated genomic instability. TP53 truncating mutations were enriched in BRCA1 carriers compared with non‐carriers and showed a trend toward worse outcomes, potentially related to lower homologous recombination deficiency scores and activation of epithelial‐mesenchymal transition pathways. These findings highlight the distinct mutational architecture of breast cancers from BRCA1 carriers and suggest that TP53 truncating mutations may define a particularly aggressive subtype that warrants further investigation.Keywords
Funding Information
- National Natural Science Foundation of China (82272932)
- National Natural Science Foundation of China (82303165)
- National Natural Science Foundation of China (82473481)
- National Natural Science Foundation of China (92359201)
This publication has 24 references indexed in Scilit:
- Impact of the addition of carboplatin to anthracycline‐taxane‐based neoadjuvant chemotherapy on survival in BRCA1/2‐mutated triple‐negative breast cancerInternational Journal of Cancer, 2020
- Accurate detection and quantification of epigenetic and genetic second hits in BRCA1 and BRCA2 -associated hereditary breast and ovarian cancer reveals multiple co-acting second hitsCancer Letters, 2018
- Multiclonal Invasion in Breast Tumors Identified by Topographic Single Cell SequencingCell, 2018
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- The somatic mutation profiles of 2,433 breast cancers refine their genomic and transcriptomic landscapesNature Communications, 2016
- Landscape of somatic mutations in 560 breast cancer whole-genome sequencesNature, 2016
- Subclonal diversification of primary breast cancer revealed by multiregion sequencingNature Medicine, 2015
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Recurrent gross mutations of the PTEN tumor suppressor gene in breast cancers with deficient DSB repairNature Genetics, 2007
- p53 mutation with frequent novel codons but not a mutator phenotype in BRCA1- and BRCA2-associated breast tumoursOncogene, 1998